MétaCan
Menu
Back to cohort
Record W4409039889 · doi:10.1038/s41591-025-03532-x

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma

2025· article· en· W4409039889 on OpenAlexaff
Sandeep Raj, Teng Fei, Shalev Fried, Andrew Ip, Joshua Fein, Lori A. Leslie, Ana Alarcón Tomás, Doris Leithner, Jonathan U. Peled, Magdalena Corona, Parastoo B. Dahi, Ivetta Danylesko, Zachary D. Epstein‐Peterson, Tyler Funnell, Sergio Giralt, Elad Jacoby, Meirav Kedmi, Ivan Landego, Richard J. Lin, Allison Parascondola, L.C. Fernando Pascual, Natali Orozco, Jae H. Park, M. Lia Palomba, Gilles Salles, Amethyst Saldia, Heiko Schöder, Inbal Sdayoor, Gunjan L. Shah, Michael Scordo, Noga Shem‐Tov, Avichai Shimoni, John Slingerland, Ronit Yerushalmi, Arnon Nagler, Benjamin D. Greenbaum, Andrew J. Vickers, Hyung C. Suh, Abraham Avigdor, Miguel‐Angel Perales, Marcel R.M. van den Brink, Roni Shouval

Bibliographic record

VenueNature Medicine · 2025
Typearticle
Languageen
FieldMedicine
TopicCAR-T cell therapy research
Canadian institutionsUniversity of Manitoba
FundersNational Center for Advancing Translational SciencesNational Cancer InstituteNational Heart, Lung, and Blood InstituteNational Institute on Aging
KeywordsLymphomaBiomarkerSignature (topology)MedicineHodgkin lymphomaImmunologyInflammatory responseInflammationOncologyCancer researchBiologyGeneticsMathematics

Abstract

fetched live from OpenAlex

Disease progression is a substantial challenge in patients with non-Hodgkin lymphoma (NHL) undergoing chimeric antigen receptor T cell (CAR-T) therapy. Here we present InflaMix (INFLAmmation MIXture Model), an unsupervised quantitative model integrating 14 pre-CAR-T infusion laboratory and cytokine measures capturing inflammation and end-organ function. Developed using a cohort of 149 patients with NHL, InflaMix revealed an inflammatory signature associated with a high risk of CAR-T treatment failure, including increased hazard of death or relapse (hazard ratio, 2.98; 95% confidence interval, 1.60–4.91; P < 0.001). Three independent cohorts comprising 688 patients with NHL from diverse treatment centers were used to validate our approach. InflaMix consistently and reproducibly identified patients with a higher likelihood of disease relapse and mortality, and it provided supplementary predictive value beyond established prognostic markers, including tumor burden. Moreover, InflaMix exhibited robust performance in cases with missing data, maintaining accuracy when considering only six readily available laboratory measures. These findings show that InflaMix is a valuable tool for point-of-care clinical decision-making in patients with NHL undergoing CAR-T therapy. A preinfusion circulatory inflammation biomarker-based signature predicts the likelihood of treatment failure in patients with non-Hodgkin lymphoma who were treated with CAR-T cell therapy, with an inflammatory cluster assignment being prognostic of clinical response and survival outcomes.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.337
Teacher spread0.328 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations43
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNature MedicineSame topicCAR-T cell therapy researchFrench-language works237,207